Deutsche version

Our goal is to create uniqueness based on scientific research

The company

Structure of United Technologies UT AG

United Technologies UT AG is a holding company incorporated in Zurich, Switzerland. It is owned by four Swiss corporate shareholders and holds investments in United Cosmeceuticals GmbH. United Technologies UT AG owns several patents on its proprietary biotechnology platform based on interleukin-1 alpha (Dermatopoietin®) and enkephalin analogues with applications in cosmetics, dermatology and other medical fields.

The main objectives of United Technologies UT AG are to further expand the scientific and business opportunities of its patented Dermatopoietin technology, to explore other biotechnological therapeutic approaches e.g. in dermatology and dentistry and to offer OEM and consulting services to the biotech industry.

Dermatopoietin® - I am the architect

Figure: Dermatopoietin is a key regulator of skin and hair renewal with many potential applications in cosmetics, dermatology and dentistry.

Company history

Key events

2007 United Technologies UT AG founded as an R&D company
2008 United Cosmeceuticals GmbH founded as a distribution company
2007 - 2009 Development of Dermatopoietin and Hexadeltine as cosmetic active ingredients
2009 Launch of EVEN of Switzerland, phased out in 2010
2010 Launch of DermatoPoietin, phased out in 2013
2013 Restructuring of United Technologies UT AG as holding company and United Cosmeceuticals GmbH as operative company for the entire value chain
2015 Launch of EVENSWISS®